{
  "ticker": "HPC",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02963691",
  "id": "02963691",
  "pages": 8,
  "price_sensitive": false,
  "date": "20250630",
  "time": "1415",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250630/pdf/06l8c8hkn33zb7.pdf",
  "summary": "### Summary of ASX Appendix 2A - Application for Quotation of Securities:  \n**Issuer:** The Hydration Pharmaceuticals Company Limited (HPC)  \n\n- **New Securities Quoted:** 3,000,000 ordinary fully paid shares (HPC)  \n- **Issue Date:** 30/06/2025  \n- **Issue Price:** AUD $0.01 per share  \n- **Total Issued Capital Post-Quotation:**  \n  - **Quoted Ordinary Shares:** 386,300,926  \n  - **Unquoted Securities:** Detailed options/warrants/rights (e.g., 46.6M options expiring Dec 2025, 99.9M warrants, etc.) \u2013 see Part 4.2 for full breakdown.  \n- **Context:** Part of a previously announced non-renounceable pro-rata rights issue (Appendix 3B dated 19-Mar-2025). Shortfall placement may occur within 3 months.  \n\n**Material Impact:**  \n- Dilution from new shares (3M at $0.01) is minimal relative to existing issued capital (~386M shares).  \n- Large volume of unquoted options/warrants (~180M+) could create future dilution if exercised.  \n\n*No other material trading or capital structure changes identified.*",
  "usage": {
    "prompt_tokens": 1833,
    "completion_tokens": 272,
    "total_tokens": 2105,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-30T04:47:58.647281"
}